Domain Associates
Domain Associates is a venture capital firm with an exclusive focus on life sciences.
Business Model:
Revenue: $8.2M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Domain Associates Information
Geographic Data
Address: 1 Palmer Sq E
City: Princeton
State: NJ
Zip: 08542
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$164M
Social
Twitter
Linkedin
Crunchbase
Metrics
4,061,660Website Global Rank
2,913Website Monthly Traffic
Twitter Followers
Description
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Contact Phone:
+16096835656
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2017 | Fractyl Health | Series D | 0 |
| 3/2005 | GenVault | Series A | 22.8M |
| 9/2016 | Rox Medical | Series E | 40M |
| 4/2003 | Ansata Therapeutics | Series B | 2.5M |
| 2/1999 | Pointshare | Series B | 7.3M |
| 10/2000 | IntraLase | Venture Round | 22M |
| 6/2012 | Benvenue Medical | Series D | 25M |
| 6/2014 | Benvenue Medical | Series E | 40M |
| 10/2007 | Optherion | Series A | 37M |
| 8/1991 | Genta | Venture Round | 8.4M |
| 5/2016 | Obalon Therapeutics | Series E | 0 |
| 4/2003 | ESP Pharma | Series B | 20M |
| 4/2007 | DiObex | Series B | 24M |
| 2/2005 | Five Prime Therapeutics | Series C | 45M |
| 12/2016 | Axial Biotherapeutics | Series A | 19.1M |
| 8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
| 10/2010 | ProteinSimple | Series F | 20M |
| 1/2007 | Esprit Pharma | Series B | 25M |
| 12/2009 | Apnex Medical | Series B | 14M |
| 9/2012 | Tandem Diabetes Care | Series D | 36.4M |
| 7/2004 | Alimera Sciences | Series A | 26.8M |
| 7/2010 | Zogenix | Venture Round | 0 |
| 4/2017 | Epic Sciences | Series D | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 8/2022 | Fractyl Health | Series F | - |
| 2/2003 | Neose Technologies, Inc | Venture Round | 17M |
| 10/2012 | Rightcare Solutions | Series A | 1.8M |
| 2/2012 | Applied Proteomics | Series B | 22.5M |
| 1/1991 | VIVUS | Seed Round | - |
| 11/2016 | Axial Biotherapeutics | Series A | 19.5M |
| 1/2017 | Adynxx | Series B | 16M |
| 7/2012 | Adynxx | Venture Round | 2M |
| 3/2003 | GenVault | Series A | 10M |
| 8/2003 | GenVault | Series A | 13M |
| 11/2006 | Aesthetic Sciences | Series A | 6M |
| 4/2014 | Smart Medical Systems | Venture Round | 6.5M |
| 12/2003 | Novalar Pharmaceuticals | Series B | 5M |
| 7/2008 | Tandem Diabetes Care | Series B | 13M |
| 1/2010 | Tandem Diabetes Care | Series C | 53M |
| 12/2002 | SkinMedica | Series B | 9M |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 10/2013 | Bionano Genomics | Series C | 0 |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 3/2007 | Adastra Pharmaceuticals | Series A | 40M |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 5/2001 | SenoRx | Venture Round | 19M |
| 2/2011 | IntegenX | Series B | 0 |
| 7/2014 | Epic Sciences | Series C | 0 |
| 6/2012 | Twelve | Series B | 15M |
| 1/2018 | Celtaxsys | Series E | - |
| 6/2015 | Celtaxsys | Series D | 0 |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2010 | Twelve | Series A | 3M |
| 9/2015 | Kona Medical | Debt Financing | 10M |
| 12/2012 | Kona Medical | Series C | 10M |
| 7/2008 | NovaDigm Therapeutics | Series A | 4.1M |
| 9/2005 | DiObex | Series A | 7.1M |
| 5/2009 | Neothetics | Series A | - |
| 2/2010 | Altair Therapeutics | Series B | 17M |
| 12/2009 | Afferent Pharmaceuticals | Series A | 23M |
| 1/2006 | CoLucid Pharmaceuticals | Series A | 0 |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 1/2015 | CoLucid Pharmaceuticals | Series C | 0 |
| 8/2011 | CoLucid Pharmaceuticals | Venture Round | 0 |
| 7/2008 | CoLucid Pharmaceuticals | Series B | 0 |
| 9/2004 | Vascular Architects | Series E | 0 |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 6/2003 | Eunoe | Venture Round | 40M |
| 8/2004 | 3F Therapeutics | Series B | 14.2M |
| 11/2004 | Ascenta Therapeutics | Series B | 30M |
| 8/2007 | Helixis | Series A | 10M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 5/2005 | Celator Pharmaceuticals | Series B | 20M |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 10/2004 | GeneOhm Sciences | Series C | 12M |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 7/2014 | Xagenic | Series B | 0 |
| 7/2015 | Xagenic | Series B | 11.8M |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 12/2009 | Regado Biosciences | Series D | 0 |
| 5/2008 | Esperion | Series A | 22.8M |
| 2/2008 | BioVascular | Series C | 10.9M |
| 11/2015 | Fractyl Health | Series C | 57M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 3/2012 | Sequent Medical | Series C | 26M |
| 4/2011 | Ocunexus Therapeutics | Series B | 0 |
| 1/2012 | Carticept Medical | Series C | 10M |
| 3/2003 | TargetRx | Series C | 0 |
| 1/2003 | Iomai Corporation | Series C | 54M |
| 3/2011 | Astute Medical | Series B | 13M |
| 7/2012 | Obalon Therapeutics | Series C | 16.5M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 7/2006 | ROX Medical | Series B | 10.1M |
| 6/2008 | ROX Medical | Series C | 33M |
| 9/2014 | Colorescience | Series B | 15M |
| 10/2013 | NovaDigm Therapeutics | Series B | 7M |
| 11/1999 | Medpool | Venture Round | 12M |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 1/2014 | Atara Biotherapeutics | Series B | 13.5M |
| 7/2020 | Nobias Therapeutics | Series A | 0 |
| 5/2020 | Seraphina Therapeutics | Series A | 0 |
| 1/2004 | Orexigen Therapeutics | Series A | 11M |
| 1/2001 | Volcano Corporation | Venture Round | - |
| 6/2015 | Milestone Pharmaceuticals | Series B | 0 |
| 3/2005 | Novalar Pharmaceuticals | Series C | 27M |
| 12/2007 | Corthera | Series C | 23M |
| 7/2013 | aTyr Pharma | Series D | 49M |
| 5/2003 | Santarus | Series D | 51.4M |
| 7/2018 | Omniome | Series B | 0 |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 1/2015 | Sera Prognostics | Series B | 20M |
| 11/2014 | Sera Prognostics | Series B | 5M |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 1/2016 | Benvenue Medical | Equity | 23M |
| 1/2003 | Vascular Architects | Series D | 0 |
| 1/2010 | The Foundry | Series A | 3M |
| 3/2007 | Regado Biosciences | Series C | 23M |
| 10/2021 | Axial Biotherapeutics | Series C | 0 |
| 11/2009 | IntegenX | Series B | 18.1M |
| 6/1999 | Cardiodynamics International | Venture Round | 5M |
| 6/2013 | Veracyte | Series C | 28M |
| 6/2008 | Meritage Pharma | Series A | 22.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 3/2013 | Atara Biotherapeutics | Venture Round | 1M |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 11/2012 | Epic Sciences | Series B | 13M |
| 7/2012 | Bionano Genomics | Series B | 0 |
| 9/2010 | Eddingpharm (Cayman) | Series B | 24M |
| 5/2002 | Onyx Pharmaceuticals | Venture Round | 20M |
| 3/2000 | SelfCare.com | Venture Round | 0 |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 9/2000 | Medpool | Venture Round | 10M |
| 9/2013 | Otonomy | Series C | 45.9M |
| 12/2000 | Molecular Staging | Series D | 41.3M |
| 1/2004 | Peninsula Pharmaceuticals | Series C | 0 |
| 1/2006 | ProteinSimple | Series B | 0 |
| 6/2016 | Miramar Labs | Venture Round | - |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 6/2015 | Sebacia | Series C | 12M |
| 4/2014 | Sequent Medical | Series D | 20M |
| 11/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 9/2000 | Senomyx | Series B | 10M |
| 4/2007 | NovaCardia | Series B | 18M |
| 9/2007 | Sequel Pharmaceuticals | Series A | 20M |
| 3/2001 | Santarus | Series C | 33.2M |
| 2/2014 | Neothetics | Series C | 8M |
| 12/2012 | Neothetics | Series C | 20.6M |
| 12/2011 | IntegenX | Series C | 40M |
| 1/2012 | Ariosa Diagnostics | Series C | 52.7M |
| 3/2011 | Bionano Genomics | Series B | 0 |
| 8/2008 | Glaukos | Series D | 35M |
| 6/2003 | Orqis Medical | Series C | 25M |
| 4/2001 | iScribe | Series D | 15M |
| 6/2018 | WindMIL Therapeutics | Series B | 0 |
| 9/2006 | Cantex Pharmaceuticals | Series B | 19M |
| 8/2006 | Esprit Pharma | Series B | 90.8M |
| 5/2007 | Apnex Medical | Series A | 16.1M |
| 1/2004 | Auxeris Therapeutics | Series A | 1.6M |
| 11/2011 | Sera Prognostics | Series A | 19.3M |
| 12/2001 | Aradigm | Convertible Note | 48.4M |
| 10/2006 | Ocunexus Therapeutics | Series A | 20M |
| 4/2004 | Imagine Pharmaceuticals | Series A | 3.7M |
| 4/2010 | Adastra Pharmaceuticals | Venture Round | 0 |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 8/2006 | Zogenix | Series A | 60M |
| 1/2008 | Zogenix | Series B | 18M |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 7/2013 | ReVision Optics | Series E | 55M |
| 10/2014 | Miramar Labs | Series D | 26M |
| 12/2012 | Evofem Biosciences | Series C | 20.6M |
| 10/2013 | NovaDigm Therapeutics | Venture Round | 7M |
| 7/2012 | Ocunexus Therapeutics | Series B | 0 |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 9/2012 | Rox Medical | Series D | 6M |
| 10/2002 | Peninsula Pharmaceuticals | Series B | 0 |
| 2/2014 | Evofem Biosciences | Series C | 8M |
| 4/2005 | 3F Therapeutics | Series C | 6M |
| 7/2008 | Celator Pharmaceuticals | Series C | 22.5M |
| 8/2007 | Celator Pharmaceuticals | Series C | 10M |
| 9/2010 | Celator Pharmaceuticals | Series D | 0 |
| 10/2005 | eNeura Therapeutics | Series B | 5.1M |
| 5/1992 | NPS Pharmaceuticals | Seed Round | 5M |
| 12/1998 | OraPharma Inc. (acquired by JNJ) | Venture Round | 16M |
| 9/2014 | Fractyl Health | Series B | 19.8M |
| 1/2015 | Obalon Therapeutics | Series D | 0 |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 4/2009 | ProteinSimple | Series C | 10M |
| 1/2009 | BiPar Sciences | Series C | 20M |
| 2/2007 | BiPar Sciences | Series B | 35M |
| 12/2005 | Celladon | Series B | 30M |
| 4/2007 | Ascenta Therapeutics | Series C | 50M |
| 7/2006 | Ocera Therapeutics | Series B | 12M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 12/2013 | Atara Biotherapeutics | Series B | 38.5M |
| 7/2003 | Corthera | Series A | 2.1M |
| 5/2009 | Marinus Pharmaceuticals | Series B | 20M |
| 5/2004 | NuVasive | Venture Round | 9.8M |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 10/2012 | Veracyte | Private Equity Round | 14.9M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 4/2013 | Esperion | Venture Round | 33M |
| 5/2007 | Asmacure Ltée | Series A | 9M |
| 6/2008 | GenVault | Series B | 13M |
| 8/2013 | Applied Proteomics | Series C | 28M |
| 4/2017 | ChromaCode | Series B | 12M |
| 12/2019 | ChromaCode | Series C | 0 |
| 4/2005 | TargetRx | Series D | 0 |
| 1/2020 | Omniome | Series C | 60M |
| 9/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 1/2005 | NeuroPace | Venture Round | 30M |
| 4/2001 | Xcel Pharmaceuticals | Venture Round | 70M |
| 9/1993 | GelTex Pharmaceuticals | Venture Round | 6.8M |
| 12/2012 | Regado Biosciences | Series E | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 4/2013 | Afferent Pharmaceuticals | Series B | 5M |
| 7/2009 | Oraya Therapeutics | Series C | 42M |
| 5/2012 | Kona Medical | Series C | 0 |
| 4/2005 | Orexigen Therapeutics | Series B | 35M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 7/2010 | ReVision Optics | Series D | 35M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 12/2001 | Pharmion | Venture Round | 65M |
| 11/2018 | Antios Therapeutics | Series A | 0 |
| 8/2010 | Otonomy | Series B | 38.5M |
| 4/2007 | GenVault | Venture Round | 18M |
| 1/2005 | GeneOhm Sciences | Series C | 0 |
| 6/2000 | Align Technology | Series D | 105M |
| 6/2000 | TargetRx | Series B | 12M |
| 4/2005 | Receptor Biologix | Series A | 33.6M |
| 10/2010 | aTyr Pharma | Series C | 23M |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 9/2005 | Esprit Pharma | Series A | 103.7M |
| 2/2012 | Apnex Medical | Series C | 20M |
| 10/2009 | Alimera Sciences | Series C | 5M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 5/2004 | GI Dynamics | Series B | 0 |
| 2/2019 | Axial Biotherapeutics | Series B | 25M |
| 6/2010 | Corridor Pharmaceuticals | Series A | 0 |
| 4/2014 | Otonomy | Series D | 49M |
| 7/2004 | SkinMedica | Series D | 30M |
| 4/2005 | SkinMedica | Series E | 0 |
| 4/2006 | SkinMedica | Series E | 0 |
| 9/2014 | Zyga Technology | Series D | 2M |
| 5/2012 | Zyga Technology | Series C | 25M |
| 7/2017 | Sebacia | Series D | 0 |
| 10/2006 | Achaogen | Series B | 26M |
| 2/2013 | Glaukos | Series F | 30M |
| 1/2004 | Novacea | Series C | 35M |
| 11/2002 | Novacea | Series B | 36M |
| 4/2015 | Twelve | Series C | 35M |
| 2/2011 | Glaukos | Series E | 0 |
| 4/2011 | Benvenue Medical | Series C | 35.5M |
| 8/2002 | Proxima Therapeutics | Series E | 14M |
| 2/2001 | Proxima Therapeutics | Series D | 17M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 12/2001 | TargetRx | Series C | 0 |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 11/2005 | Alimera Sciences | Series B | 31.8M |
| 1/2008 | Sonexa Therapeutics | Series A | 0 |
| 6/2004 | Somaxon Pharmaceuticals | Series B | 23M |
| 10/2009 | Zogenix | Series B | 36M |
| 3/2008 | Alimera Sciences | Series C | 30M |
| 11/2019 | Truvian Sciences | Series B | 27.1M |
| 11/2004 | Corthera | Series B | 15M |
| 3/2000 | iScribe | Series B | 21M |
| 10/1999 | Align Technology | Venture Round | 0 |
| 6/2010 | Veracyte | Series B | 28M |
| 5/2000 | Beansprout.net | Series C | 21.3M |
| 7/2020 | Exalys Therapeutics | Series A | 15M |
| 12/2007 | REVA Medical | Venture Round | 42M |
| 2/2007 | Carticept Medical | Series A | - |
| 3/2007 | Orqis Medical | Series D | 12M |
| 4/2007 | ReVision Optics | Series D | 25M |
| 2/2008 | Obalon Therapeutics | Series A | 4.7M |
| 11/2016 | Gene Sciences, Inc. | Series A | 8M |
| 10/2004 | Vanda Pharmaceuticals | Series B | 18.5M |
| 12/1987 | Viagene | Seed Round | 1M |
| 3/2010 | Carticept Medical | Series B | 20M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 7/2005 | Immune Control | Series A | 0 |
| 1/2016 | Singular Genomics | Seed Round | - |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 9/2002 | Glaukos | Series A | 10M |
| 4/2005 | NovaCardia | Series A | - |
| 9/2006 | NovaCardia | Series B | 48M |
| 10/2012 | Cotera | Venture Round | 5M |
| 4/2013 | ReVision Optics | Equity | 15M |
| 11/2013 | Rightcare Solutions | Series B | 5M |
| 6/2007 | Evoke Pharma | Series A | 3.3M |
| 5/2010 | Sequent Medical | Series B | 15.6M |
| 10/2005 | Marinus Pharmaceuticals | Series A | 29.4M |
| 1/2013 | Marinus Pharmaceuticals | Series C | 21M |
| 8/2020 | Fractyl Health | Series E | 0 |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 11/2002 | Altea Therapeutics | Series B | 17M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 6/2003 | GI Dynamics | Series A | 4.1M |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 10/2021 | Axial Biotherapeutics | Series C | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 8/2020 | Fractyl Health | Series E | 0 |
| 7/2020 | Nobias Therapeutics | Series A | 0 |
| 7/2020 | Exalys Therapeutics | Series A | 0 |
| 5/2020 | Seraphina Therapeutics | Series A | 0 |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 1/2020 | Omniome | Series C | 0 |
| 12/2019 | ChromaCode | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
